BIOCQ (Biocept) FCF Margin %: -540.41% (As of Jun. 2023)


BIOCQ Biocept Inc BIOCQ
16 GF Score
Price $0.00
View Full Analysis

What is Biocept FCF Margin %?

Biocept BIOCQ 16 FCF Margin % is -540.41% as of Jun. 2023. GuruFocus rates BIOCQ with a GF Score™ of 16/100.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biocept's Free Cash Flow for the three months ended in Jun. 2023 was $-3.18 Mil. Biocept's Revenue for the three months ended in Jun. 2023 was $0.59 Mil. Therefore, Biocept's FCF Margin % for the quarter that ended in Jun. 2023 was -540.41%.

As of today, Biocept's current FCF Yield % is -1,827,700.00%.

The historical rank and industry rank for Biocept's FCF Margin % or its related term are showing as below:

BIOCQ' s FCF Margin % Range Over the Past 10 Years
Min: -1347.86   Med: 0   Max: 0
Current: -1347.86

BIOCQ's FCF Margin % is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: -1.845 vs BIOCQ: -1347.86

Biocept FCF Margin % Related Terms

Biocept FCF Margin % Historical Data

* Premium members only.

The historical data trend for Biocept's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocept FCF Margin % Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -692.31 -430.17 -75.21 3.46 -54.51

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -73.16 -440.02 479.52 -933.88 -540.41

BIOCQ vs IDTA, DIGP, ABMC: FCF Margin % Comparison

For the Diagnostics & Research subindustry, Biocept's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocept FCF Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Biocept's FCF Margin % falls into.


BIOCQ
16GF Score
Biocept Inc BIOCQ
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocept FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Biocept's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-14.096/25.858
=-54.51 %

Biocept's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-3.183/0.589
=-540.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -540.41% mean?
Biocept (BIOCQ) has a FCF Margin % of -540.41% as of Jun. 2023. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biocept and its competitors.
Is Biocept's FCF Margin % too high?
Biocept's current FCF Margin % is -540.41%. Overall, Biocept has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biocept's FCF Margin % compare to IDTA and DIGP?
Biocept's FCF Margin % of -540.41% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biocept and its competitors. Biocept's current FCF Margin % is -540.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocept stock overvalued right now?
Biocept (BIOCQ) has a current FCF Margin % of -540.41%. The current FCF Margin % is -540.41%. Biocept's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biocept (BIOCQ), the current FCF Margin % is -540.41% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocept Business Description

Address 9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
16GF Score

Get the complete analysis for BIOCQ

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price